Scott Ramsey, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses determining cost effectiveness of novel treatments, such as immuno-oncology agents, and potential solutions to reducing financial toxicity in cancer care.
Scott Ramsey, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses determining cost effectiveness of novel treatments, such as immuno-oncology agents, and potential solutions to reducing financial toxicity in cancer care.
Transcript
In what ways would the current standard survival modeling be inadequate for determining cost effectiveness of novel treatments that cure or produce substantially longer term responses?
Standard survival modeling relies on the distribution of survival that can be easily modeled with common functional forms. And what we’re learning with some of the new immuno-oncology agents is that there can be, in some cases, a fraction of patients who have long-term responses, and in effect, cures, such that their survival approach is that of the normal population without the disease. These are very hard to capture—essentially impossible to capture—with standard survival modeling techniques, so cure model fractions were developed to try to address this problem.
With the cost of cancer steadily increasing, what, if any, solutions do you see that could reduce financial toxicity?
I do have hope that value-based pricing or performance-based pricing might be one way to address the problem of financial toxicity. I think it's also important for the insurance community, which is turning more of the cost of care over to patients, understand that for oncology this is creating tremendous burdens. So it will be a variety of solutions, both on the payer side, on the manufacturer side, and also on the physician and patient side to make better decisions so that problem is mitigated.
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
May 1st 2024The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.
Read More